Drug companies tend to get priced on what they are about to lose rather than what they have just launched.

Stick with us, and you will get the full picture before earnings on the 29th, including a schizophrenia drug whose revenue grew 81% and the trial result that still knocked the shares.

Forestry

Weyerhaeuser Company (NYSE: WY) gained a fresh catalyst today as Bank of America upgraded the stock from Neutral to Buy. The firm set a $25 target, 32% above the $18.90 price, arguing that asset-backed companies become attractive when industry sentiment is weak.

The valuation looks modest compared with the company’s physical holdings. Weyerhaeuser owns more than 10 million acres of U.S. timberland but carries a market value near $13.6 billion.

Its last four timberland sales averaged about $2,837 per acre, more than twice the equity value of each owned acre at the current capitalization.

At $18.90, you are paying for a depressed lumber cycle even though second-quarter net income rose to $162 million from $87 million. Revenue reached $1.87 billion, adjusted EPS beat expectations, and higher lumber and western log prices helped earnings recover despite weak housing activity.

The Forests Carry Their Own Value

Timberland does not lose its productive capacity because home construction slows. Trees continue growing, harvests can be deferred, and acreage can support recreational leases, conservation agreements, renewable-energy projects, and land sales.

Those characteristics give Weyerhaeuser several ways to preserve value while waiting for lumber demand to improve.

Housing Weakness Can Last

Elevated mortgage rates could keep homebuilding subdued, while lower lumber prices would pressure cash generation and dividend coverage. Land transactions may also arrive unevenly, preventing the discount from closing quickly.

Patience belongs in your time horizon, but the forests, improving profit, and a fresh Buy rating provide more support than the share price implies.

Refining

Delek US Holdings (NYSE: DK) has a fresh catalyst after the Trump administration invoked the Defense Production Act to support an expansion of its Tyler, Texas refinery. The project aims to increase commercial and military-grade fuel production at a facility that processes about 74,000 barrels per day.

Delek carries a market value near $5 billion and generated approximately $681 million in trailing free cash flow. That places the stock around 7.3 times free cash flow, a restrained multiple for a refiner receiving direct federal support for additional capacity.

The company already operates four refineries with combined capacity of 302,000 barrels per day. If federal involvement lowers financing, permitting, or infrastructure barriers at Tyler, you gain exposure to a larger earnings base without paying for the expansion in advance.

Federal Support Changes the Equation

The Defense Production Act gives the project strategic importance beyond ordinary refinery spending.

Additional military-fuel capability can deepen Delek’s relationship with government customers, while higher commercial output offers another route to turn added capacity into cash flow. Recent cash generation also means the thesis does not depend entirely on future construction or immediate margin expansion.

Important Details Remain Undisclosed

Washington has not disclosed the funding amount, final capacity increase, construction cost, or completion schedule. Refining margins can contract quickly when fuel supply rises or crude-price spreads narrow.

Still, your entry point combines an established refining network, strong recent cash generation, and government-backed expansion potential at a multiple that reflects limited confidence in future growth.

Biotechnology

Liquidia Corporation (NASDAQ: LQDA) removed a major obstacle by settling six lawsuits with United Therapeutics over Yutrepia, its pulmonary arterial hypertension treatment. The agreement keeps Yutrepia available for PAH patients, ending litigation that had erased more than half the stock’s value after an adverse September ruling.

Commercial performance strengthened while the legal fight dominated attention. Liquidia reported preliminary third-quarter Yutrepia sales of $222.7 million, ahead of the $201.5 million Wall Street estimate, after second-quarter sales reached $170.4 million and adjusted EBITDA totaled $96.3 million.

At a market value near $3.1 billion, Liquidia trades around 23.5 times trailing earnings, 13.5 times EBITDA, and 15.9 times free cash flow.

Those figures leave you comparing a rapidly growing drug launch against multiples that remain moderate for a newly profitable biotechnology company.

Legal Clarity Restores the Growth Story

Yutrepia will lose its PH-ILD indication, but Liquidia can continue selling the drug for PAH, where roughly 45,000 treated patients represent a substantial market.

The settlement allows management to redirect legal spending toward commercial execution and the late-stage L606 program.

One Drug Still Carries the Thesis

Liquidia must pay United Therapeutics approximately $380.7 million through 2027, and removing PH-ILD narrows Yutrepia’s addressable market. Dependence on one commercial product also leaves earnings exposed to competition, reimbursement decisions, or weaker prescription growth.

Even after today’s rally, resolved litigation and better-than-expected sales support a credible revaluation, but any position inside your speculative allocation should reflect the remaining concentration.

Bristol Myers Squibb (NYSE: BMY)

Bristol Myers makes prescription drugs, and the one everybody fixates on is Eliquis, a blood thinner facing US generic competition as early as April 2028 under existing settlements. That date is the central worry, and it is why a company this size trades at under nine times forward earnings with a dividend above four percent. Here is the odd part.

It reported two successful late-stage trials, admilparant at the lower dose hitting its main lung-function target in pulmonary fibrosis and RYZ101 working in a type of neuroendocrine tumor, yet shares fell 2.6% that day and another 1.6% the next because the higher admilparant dose missed.

Meanwhile, the newer products already make up about 59% of revenue and grew 14% last quarter excluding currency moves, and Cobenfy, its schizophrenia treatment, grew 81% off a small base. None of this is guaranteed to replace Eliquis, and the next big readout is Milvexian in atrial fibrillation.

Devon Energy (NYSE: DVN)

Devon produces oil and gas across several US shale basins, with its biggest position in the Delaware Basin. It got considerably larger on May 7, when it completed an all-stock merger with Coterra that implied a combined enterprise value near $58 billion at the announced terms, leaving Devon holders with roughly 54% of the company.

The acreage overlaps give the combined business a real chance to coordinate development and strip out costs, and management is targeting $1 billion in annual pre-tax savings by the end of 2027.

You are paying a bit over nine times forward earnings, with a dividend near two and a half percent. What stands out is the agreement: 26 of the 30 analysts covering it rate it Buy or better, with an average target about 20% higher. Results land November 5 after the close, with the call the next morning.

Molson Coors (NYSE: TAP)

Molson Coors sells beer, including Coors Light, Miller Lite, Blue Moon and Carling. Beer volumes have been under pressure in its main markets, and the stock has been priced accordingly, leaving a household name paying a dividend above five percent on forward earnings of under eight times. Here is what that misses.

The company has raised its dividend every year since 2022, and the average analyst target sits roughly nineteen percent above the current price. The bear case is simple and real, which is that beer keeps losing share of the drinks cabinet, and a yield that high always carries some risk of a cut.

The counter is that you are collecting over five percent a year while you find out how slowly that runs. Third quarter results are due in early November.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge